Date:2/12/2013

basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for income (loss) from operations, net income (loss) or income (loss) per diluted share prepared in accordance with U.S. GAAP.  Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Table 1.  Our projected 2013 adjusted EPS, however, is only provided on an adjusted basis.  It is not feasible to provide GAAP EPS guidance because the items excluded are difficult to predict and estimate and are primarily dependent on future events.Albany Molecular Research, Inc.
Condensed Consolidated Statements of Operations (unaudited)Three Months EndedYear Ended(Dollars in thousands, except for per share data)December 31,
2012December 31,
2011December 31,
2012December 31,
2011Contract revenue$   59,131$   39,412$   189,858$  169,611Recurring royalties8,0817,18035,98835,034Milestone revenue──8403,000Total revenue67,21246,592226,686207,645Cost of contract revenue48,48340,354168,064168,470Technology incentive award6707183,1433,557Research and development1061,8179067,939Selling, general and administrative10,4439,36840,90441,071Restructuring charges8893204,6321,271Impairment charges4,36721,3428,33421,342Arbitration charge───127Total operating expenses64,95873,919225,983243,777Income (loss) from operations2,254(27,327)703(36,132)Interest expense, net(90)(256)(454)(583)Other income (expense), net971(57)(130)77Income (loss) before income taxes 3,135(27,640)119(36,638)Income tax expense (benefit)1,219(3,231)3,896(4,342)Net income (loss) $
,916$   (24,409)$
(3,777)$   (32,2967)Basic and diluted income (loss) per share$
.07$
(0.81)$
(0.12)$
(1
'/>"/>

SOURCE AMRI Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
2. The In View Series Announces Plans for a New Series on 3D-Printing
3. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
4. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
5. Murray Test Prep Announces the Launch of their Online Tutoring Services
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
9. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
10. Spectrum Announces bioWorld Distribution Agreement
11. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results